A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer (H-20431)

This study will look at whether or not Arimidex plus Faslodex combined is superior to Arimidex alone. Patients must have advanced or metastatic breast cancer that is hormone receptor positive (ER+ and/or PR+, HER2-) Subjects must be post-menopausal to participate with no prior history of treatment for breast cancer. Study medication (Arimidex and Faslodex) are provided free of charge.

For study details see Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer (PACT001).